Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CDKN2A negative |
Therapy | Everolimus + Palbociclib |
Indication/Tumor Type | lung non-small cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CDKN2A negative | lung non-small cell carcinoma | sensitive | Everolimus + Palbociclib | Preclinical - Cell culture | Actionable | In a preclinical study, Ibrance (palbociclib) and Afinitor (everolimus) synergisticaly inhibited growth of Cdkn2a-null non-small cell lung cancer cell lines in culture (PMID: 30647837). | 30647837 |
PubMed Id | Reference Title | Details |
---|---|---|
(30647837) | CDK4/6 inhibition stabilizes disease in patients with p16-null non-small cell lung cancer and is synergistic with mTOR inhibition. | Full reference... |